(Total Views: 553)
Posted On: 02/16/2020 5:17:58 PM
Post# of 72444
Those claiming $10 for Brilacidin is a good deal for investors IMO have no clue whatsoever as to what the potential of Brilacidin is - IBD revenues around $45B/yr, OM a couple of billion, UP say .5 Billion so if IPIX licensees see just a capture rate of 15% of the market that totals somewhere around $5B/yr for 15 yrs at least. Remember, so far ALL IPIX indications have the BEST possible delivery systems and a history of excellent safety and efficacy.
Now what is Brilacidin worth as an antibiotic, maybe a COPD game changer, dermatology applications, eye/ear infections, and the list goes on and on.
$10 is a nice return, but if the value of Brilacidin turns out to be something of the order as to what thalidomide did for Regeneron, then the street would say investors were complete fools, PT Barnum poster children, for selling it off so cheap. BP would have made the steal of the century.
I say go slow and sell each parcel as its value becomes known. If it turns out to be $10, so be it, but I think it goes far, far beyond that figure.
Now what is Brilacidin worth as an antibiotic, maybe a COPD game changer, dermatology applications, eye/ear infections, and the list goes on and on.
$10 is a nice return, but if the value of Brilacidin turns out to be something of the order as to what thalidomide did for Regeneron, then the street would say investors were complete fools, PT Barnum poster children, for selling it off so cheap. BP would have made the steal of the century.
I say go slow and sell each parcel as its value becomes known. If it turns out to be $10, so be it, but I think it goes far, far beyond that figure.
(13)
(1)Scroll down for more posts ▼
